Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.

You may also be interested in...



Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected

Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.

Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected

Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.

Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation

Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel